Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AstraZeneca’s Breztri will overcome late entry to COPD market

Following the news that the Food and Drug Administration granted AstraZeneca’s Breztri approval in the US for chronic obstructive pulmonary disease (COPD); Angad Lotay, MPharm, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Despite its late market entry, GlobalData believes AstraZeneca will still catapult ahead, not only in COPD patients, but eventually […]
Read more

AstraZeneca’s, Johnson & Johnson/AbbVie’s and BeiGene’s oncology therapies repurposed for COVID-19 have class effect undermined by dissimilarities, says GlobalData

Although AstraZeneca, Johnson & Johnson/AbbVie and BeiGene all have oncology therapies, known as BTK inhibitors, repurposed for COVID-19 treatment, there are still important nuanced differences, according to reporting by Ayisha Sharma, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Sharma says: “In particular, AstraZeneca’s Calquence could have a […]
Read more

Number of US COVID-19 clinical trials surpasses China, says GlobalData

There are more than 1,039 COVID-19 potential drugs and 2,737 clinical trials for COVID-19 globally, with more than 430 of these being run in the US, despite the pandemic causing disruptions in clinical trials, says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “The US has the highest number […]
Read more

Social media posts about COVID-19 and vaccines by infectious diseases influencers peaked in March

Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from infectious diseases influencers increased significantly, with content peaking in March, says GlobalData, a leading data and analytics company. Using GlobalData’s Infectious Diseases Influencer database, Twitter posts relating to COVID-19 have been tracked and analyzed from January to May. […]
Read more

Incyte’s Jakafi poised to become leader in rapidly growing GvHD market

Following today’s news (Thursday 23 July) that Incyte’s Jakafi (ruxolitinib) met its primary endpoint in its Phase III REACH-3 chronic graft-versus-host-disease (GvHD) study; James Mather, MChem, Managing Immunology & Respiratory Analyst at GlobalData, a leading data and analytics company, offers his view: “In the top-line results announced by Incyte, Jakafi demonstrated a superior overall response […]
Read more

Social media posts about links between obesity, diet and COVID-19 by metabolic disorders influencers peaked in May, says GlobalData

Since COVID-19 was declared a pandemic in March 2020, social media posts related to the virus from metabolic disorders influencers increased significantly, with content peaking in April, says GlobalData, a leading data and analytics company. According to GlobalData’s Metabolic Disorders Influencer database, one of the main topics that metabolic disorders influencers discussed in April and […]
Read more

COVID-19 has pushed infectious disease drugs to be top CSAs, says GlobalData

Infectious disease drugs have overtaken oncology as the year’s top therapy area for contract service agreements (CSAs) as companies are shifting their current focus to developing treatments to battle the COVID-19 pandemic. COVID-19 may also be disrupting other therapy areas by reducing service agreements for other non-COVID-19 drugs, as clinical trials are being disrupted by […]
Read more

Social media posts about increased risk of stroke with COVID-19 by cardiovascular influencers peaked in May, says GlobalData

Since COVID-19 was declared a pandemic in March 2020, social media posts related to COVID-19 from cardiovascular influencers increased significantly, with content peaking in April, says GlobalData, a leading data and analytics company. Using GlobalData’s Cardiovascular Influencer database, there were only eight and 36 COVID-19-related posts in January and February, respectively, which increased to over […]
Read more

SNG001 positive interim results for COVID-19 are encouraging

Following Synairgen’s positive interim results from its inhaled interferon beta therapy, SNG001; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her view: “Synairgen is now one of a select few drugs that have shown improvements in the progression of mechanical ventilation for COVID-19, reducing those having to receive this treatment […]
Read more

Fear of second wave of COVID-19 in Australia

Australia’s initial response to the novel coronavirus was among the most successful worldwide. However, a recent increase in daily confirmed cases since the start of July has led to fears of a second wave of transmission and questions have arisen as to whether the original control measures taken by Australia were adequate, says GlobalData, a […]
Read more

Biogen can maintain dominance in SMA by demonstrating Spinraza benefits patients after Zolgensma treatment

Following the news that Biogen is planning a Phase IV trial to test Spinraza (nusinersen) in patients with spinal muscular atrophy (SMA) who have already been treated with Novartis’ gene therapy Zolgensma (onasemnogene abeparvovec); Philippa Salter, Neurology Analyst at GlobalData, a leading data and analytics company, offers her view: “Biogen can maintain its dominance in […]
Read more
1 … 83 84 85 86 87 … 108